References
- Warren RE. The stepwise approach to the management of type 2 diabetes. Diabetes Res Clin Pract 2004;65(Suppl 1):S3–8
- Matthews DR, Cull CA, Stratton IM et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297–303
- Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(Suppl 3A):3S–9S
- Home PD, Boulton AJM, Jimenez J, et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 2003;20:63–71
- Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–63
- Goudswaard, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004;18:CD003418
- Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
- Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442–51
- Robertson, C., Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control. Diabetes Educ 2006;32:423–32
- Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006;12(Suppl 1):42–6
- The European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16:716–30
- Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254–9
- Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 30/70, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307–13
- Garber A, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes Metab 2006;8:58–66
- Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–5
- Kann P, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527–32
- Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26: 2034–44
- Korytkowski M, Niskanen L, Asakura T. FlexPen®: addressing issues of confidence and convenience in insulin delivery. Clin Therap Suppl 2005;27:S89–100
- Morozova A, Sayfullina M, Vedeneeva L et al. Biphasic insulin aspart 30, a premix analogue, is an effective and well-tolerated starter insulin in type 2 diabetes. Diabetologia 2005;48(Suppl 1):A311